NICE (UK): Ruxolitinib cream is not recommended, within its marketing authorisation, for treating non-segmental vitiligo with facial involvement in people 12 years and over. This recommendation is not intended… read more.
Researchers from RMIT University have developed a wearable wound monitoring device with integrated sensors that could reduce infection risks by minimising the need for frequent physical contact. Standard… read more.
Aging skin stretches, contracts and buckles under pressure – and that’s how wrinkles form, according to new experimental evidence from scientists at Binghamton University, State University of New… read more.
Millions worldwide suffer from UV-induced skin damage, photoaging, and skin cancer annually. Current sunscreen efficacy testing relies on minimal erythema dose (MED) and minimal persistent pigment dose (MPPD);… read more.
Against the backdrop of high market demand for effective anti-ageing cosmetics, a team of Chinese researchers assessed the clinical effectiveness of a 0.1 % pterostilbene-containing skincare emulsion against a… read more.
Increased activity in a specific biological pathway may explain why many patients with a deadly form of skin cancer do not respond to the latest cancer treatments, a… read more.
New research published in Allergy indicates that certain environmental exposures may affect a child’s risk of developing atopic eczema, a condition characterized by dry, itchy, and inflamed skin. In other… read more.
The FDA has approved Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine-1… read more.
New results show Eli Lilly and Company’s Ebglyss achieved deep and sustained response for patients with moderate-to-severe atopic dermatitis (eczema) at three years. These findings from the ADjoin… read more.
Late-breaking results from Eli Lilly and Company and Incyte found adolescent patients (ages 12 to under 18) with severe alopecia areata (AA) treated with once-daily, oral baricitinib 4… read more.
Researchers at the National Institutes of Health (NIH) have determined that dermatitis resulting from topical steroid withdrawal (TSW) is distinct from eczema and is caused by an excess… read more.
Galderma announced that the European Commission has approved Nemluvio (nemolizumab) for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is now approved for… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
